Market Place
Sourcing Support
Two fitusiran Phase 3 studies published
04 Apr 2023 //
GLOBENEWSWIRE
Sanofi trumpets data with haemophilia treatment duo at ISTH
11 Jul 2022 //
PHARMAPHORUM
Sanofi`s hemophilia drug reduced bleeding in phase 3 studies
15 Dec 2021 //
BIOPHARMADIVE
Data from two Ph3 studies demonstrating fitusiran significantly reduced bleeds
14 Dec 2021 //
GLOBENEWSWIRE
Pfizer/BioNTech, Moderna expect data on shot`s protection against new variant
27 Nov 2021 //
REUTERS
Alnylam Pharmaceuticals Reports Q3 2021 Financial Results and Highlights
28 Oct 2021 //
BUSINESSWIRE
Sanofi delays hemophilia filing 18 months amid safety concerns
12 Dec 2020 //
FIERCE BIOTECH
Sanofi to resume dosing in fitusiran clinical studies in the U.S.
10 Dec 2020 //
SANOFI
Sanofi accepts a lengthy delay as its hemophilia drug fitusiran a PhIII after
10 Dec 2020 //
ENDPTS
Alnylam`s RNAi therapy Givlaari shows lasting effect one year into treatment
30 Jun 2020 //
FIERCE PHARMA
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
11 Jun 2020 //
NEJM
Alnylam Announces Publication of ENVISION PH3 Study Results for Givosiran
10 Jun 2020 //
BUSINESSWIRE
Givlaari approved in EU following recent CHMP nudge
05 Mar 2020 //
PHARMATIMES
Givlaari, Nubeqa among Jan CHMP decisions
03 Feb 2020 //
PHARMATIMES
CHMP Recommends 15 Medicines, Extends Six Indications
31 Jan 2020 //
RAPS
Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran)
31 Jan 2020 //
BUSINESSWIRE
Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
15 Jan 2020 //
FIERCE PHARMA
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
27 Nov 2019 //
RAPS
FDA`s rapid review pace nets an early approval for Alnylam`s second drug
22 Nov 2019 //
BIOPHARMADIVE
Alnylam scores speedy FDA approval for rare liver disease
21 Nov 2019 //
FIERCE PHARMA
Latest Alnylam data underscores positive results for new RNAi drug candidate
16 Apr 2019 //
BUSINESSWIRE
Alnylam spotlights just how good the efficacy data are for givosiran
13 Apr 2019 //
ENDPTS
Alnylam’s givosiran hits the mark in phase 3 porphyria test
06 Mar 2019 //
FIERCE BIOTECH
Alnylam shores up enthusiasm for givosiran with early dataset
07 Feb 2019 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.